癌の免疫療法における標的としてのCD70:進歩,課題,将来の方向性
Ruchen Wu1, Junze Chen1, Gang Wang1,2,3
1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Frontiers in oncology
|September 2, 2025
まとめ
CD70はがんの免疫療法における有望な標的であり,腫瘍では過剰発現するが,健康な組織ではそうではない. CD70を標的とする治療は 副作用が少ない腫瘍特有の治療の可能性を秘めています
科学分野:
- 腫瘍学
- 免疫学
- 分子生物学
背景:
- 癌の免疫療法では 腫瘍と戦うために 免疫系を利用します
- 効果的な安全ながん治療には 分子標的を特定することが重要です
- TNFファミリーのメンバーであるCD70は,腫瘍特異的な発現により,治療目標として有望である.
研究 の 目的:
- CD70を標的とする癌の免疫療法における最近の進歩をレビューする.
- CD70指向のアプローチの治療の可能性と限界を評価する.
- CD70ベースの治療法の将来的な臨床翻訳を導くために.
主な方法:
- 最近の科学出版物の文献レビュー
- 様々ながんにおけるCD70発現に関するデータの合成.
- CD70療法における免疫学的結果と投与システムの分析
主要な成果:
- 血液学的悪性腫瘍や固体腫瘍ではCD70が過剰発現している.
- 健康な組織におけるCD70の制限された発現は,標的治療の可能性を示唆する.
- CD70調節に対する免疫反応の最適化や理解が課題です.
結論:
- CD70を標的とした免疫療法は,がん治療において有望である.
- 微分表現は,潜在的に毒性が低下した腫瘍特有の細胞毒性を可能にします.
- 現在の課題を克服し,臨床応用を進めるためにさらなる研究が必要です.
関連する概念動画
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
01:30Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K